← Back to Search

CAR T-cell Therapy

Mana 312 for Acute Myeloid Leukemia

Phase 1
Waitlist Available
Led By Lou Vaickus, MD
Research Sponsored by Mana Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Select
Subject has a donor who has agreed to donate leukocytes for manufacture of Mana 312 and who is the same donor who provided cells for the subject's current HSCT.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's safe and effective in treating people with AML or MDS after a stem cell transplant.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Escalation Cohorts: Identify the Maximum Tolerated Dose (MTD) of Mana 312 based on the safety and tolerability of single and multiple doses.
Escalation Cohorts: Identify the Recommended Phase 2 Dose (RP2D) of Mana 312 based on the safety and tolerability of single and multiple doses.
Expansion Cohort: Assess preliminary antitumor efficacy of Mana 312 by CR.
+1 more
Secondary outcome measures
Escalation Cohorts: Assess preliminary evidence of Mana 312 antitumor efficacy by CR.
Escalation Cohorts: Assess preliminary evidence of Mana 312 antitumor efficacy by PFS.
Expansion Cohort: Confirm safety of the RP2D by measurement of TEAEs.
Other outcome measures
Assess potential cytokine induction pharmacodynamic markers of Mana 312
Characterize the anti-drug antibody (ADA) response to Mana 312.
Characterize the pharmacokinetics (PK) by measurement of Mana 312 cell counts
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Mana 312Experimental Treatment1 Intervention
Mana 312 is administered intravenously (IV) within 30 minutes in either an inpatient or outpatient setting; either a central or peripheral IV line may be used. Each cycle of administration of Mana 312 will be 28 days. Subjects not experiencing dose-limiting toxicity (DLT) following their initial dose may continue receiving their assigned Mana 312 dose every 28 days for an additional 2 doses

Find a Location

Who is running the clinical trial?

Mana TherapeuticsLead Sponsor
Lou Vaickus, MDPrincipal InvestigatorMana Therapeutics Interim Chief Medical Officer
1 Previous Clinical Trials
116 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025